127 related articles for article (PubMed ID: 34238341)
1. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.
Yin P; Meng J; Chen J; Gao J; Wang D; Liu S; Guo Q; Zhu M; Zhang G; Liu Y; Li Y; Zhang G
Virol J; 2021 Jul; 18(1):142. PubMed ID: 34238341
[TBL] [Abstract][Full Text] [Related]
2. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
Xie X; Jiang Y; Zeng Y; Liu H
Antivir Ther; 2020; 25(4):233-239. PubMed ID: 32496210
[TBL] [Abstract][Full Text] [Related]
3. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study.
He XL; Zhou YY; Fu W; Xue YE; Liang MY; Yang BH; Ma WL; Zhou Q; Chen L; Zhang JC; Wang XR
Curr Med Sci; 2021 Dec; 41(6):1096-1104. PubMed ID: 34515914
[TBL] [Abstract][Full Text] [Related]
4. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
5. Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study.
Zhou X; Hou H; Yang L; Ding G; Wei T; Li C; Heng Y; Liu R; Ma M; Hu Z; Huang L; Xu X; Hu Q; Zhao Y; Xing W; Zhao Z
J Glob Health; 2021; 11():05017. PubMed ID: 34326998
[TBL] [Abstract][Full Text] [Related]
6. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
Lan X; Shao C; Zeng X; Wu Z; Xu Y
Int J Clin Pharmacol Ther; 2021 May; 59(5):378-385. PubMed ID: 33624583
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
[TBL] [Abstract][Full Text] [Related]
10. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
A Malhani A; A Enani M; Saheb Sharif-Askari F; R Alghareeb M; T Bin-Brikan R; A AlShahrani S; Halwani R; Tleyjeh IM
PLoS One; 2021; 16(6):e0252984. PubMed ID: 34111191
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy and safety of lopinavir/ritonavir and arbidol in patients with coronavirus disease 2019].
Wen CY; Xie ZW; Li YP; Deng XL; Chen XT; Cao Y; Ou X; Lin WY; Li F; Cai WP; Li LH
Zhonghua Nei Ke Za Zhi; 2020 Aug; 59(8):605-609. PubMed ID: 32388937
[No Abstract] [Full Text] [Related]
12. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.
Li C; Luo F; Liu C; Xiong N; Xu Z; Zhang W; Yang M; Wang Y; Liu D; Yu C; Zeng J; Zhang L; Li D; Liu Y; Feng M; Liu R; Mei J; Deng S; Zeng Z; He Y; Liu H; Shi Z; Duan M; Kang D; Liao J; Li W; Liu L
Ann Med; 2021 Dec; 53(1):391-401. PubMed ID: 33620016
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study.
Li H; Xiong N; Li C; Gong Y; Liu L; Yang H; Tan X; Jiang N; Zong Q; Wang J; Lu Z; Yin X
Int J Infect Dis; 2021 Mar; 104():641-648. PubMed ID: 33515771
[TBL] [Abstract][Full Text] [Related]
14. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.
Xin S; Cheng X; Zhu B; Liao X; Yang F; Song L; Shi Y; Guan X; Su R; Wang J; Xing L; Xu X; Jin L; Liu Y; Zhou W; Zhang D; Liang L; Yu Y; Yu R
Biomed Pharmacother; 2020 Sep; 129():110500. PubMed ID: 32768975
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
[TBL] [Abstract][Full Text] [Related]
16. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, China.
Zuo Y; Liu Y; Zhong Q; Zhang K; Xu Y; Wang Z
J Med Virol; 2020 Nov; 92(11):2666-2674. PubMed ID: 32492211
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of Arbidol in the management of COVID-19 infection.
Jie X; Hongmei Y; Ping F; Kuikui Z; Bohan Y; Rui M
Aging (Albany NY); 2021 Apr; 13(7):9253-9264. PubMed ID: 33811756
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
20. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
